Pediatric drug formulations

Hannah Batchelor; Issraa Al-Obaidi; Tsutomu Harada; Jumpei Saito

doi:10.1016/B978-0-323-88459-4.00022-5

Pediatric drug formulations

Hannah Batchelor, Issraa Al-Obaidi, Tsutomu Harada, Jumpei Saito

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Age-appropriate drug formulations are not always readily available, which historically has led to sub-optimal therapy for children. Legislation introduced in the past 20 years has required that pediatric drug formulations are required for any newly licensed drug (unless a waiver is agreed). This chapter will highlight the unique challenges associated with the design and development of pediatric formulations. It will also provide an overview of the progress and the innovations as well as the challenges and the opportunities related to pediatric-adapted drug formulation development.

Original language	English
Title of host publication	Essentials of Translational Pediatric Drug Development
Subtitle of host publication	From Past Needs to Future Opportunities
Editors	Elke Gasthuys, Karel Allegaert, Lien Dossche, Mark Turner
Publisher	Elsevier
Chapter	22
Pages	561-591
Number of pages	31
ISBN (Electronic)	9780323884594
ISBN (Print)	9780323904292
DOIs	https://doi.org/10.1016/B978-0-323-88459-4.00022-5
Publication status	Published - 1 Jan 2024

Keywords

Acceptable
Age-appropriate
Design
Development
Excipient
Formulation
Oral medications
Palatable
Pediatric
Taste-masking
Therapeutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-323-88459-4.00022-5

Cite this

@inbook{87481b097f504f709b69e8b595291205,

title = "Pediatric drug formulations",

abstract = "Age-appropriate drug formulations are not always readily available, which historically has led to sub-optimal therapy for children. Legislation introduced in the past 20 years has required that pediatric drug formulations are required for any newly licensed drug (unless a waiver is agreed). This chapter will highlight the unique challenges associated with the design and development of pediatric formulations. It will also provide an overview of the progress and the innovations as well as the challenges and the opportunities related to pediatric-adapted drug formulation development.",

keywords = "Acceptable, Age-appropriate, Design, Development, Excipient, Formulation, Oral medications, Palatable, Pediatric, Taste-masking, Therapeutics",

author = "Hannah Batchelor and Issraa Al-Obaidi and Tsutomu Harada and Jumpei Saito",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-88459-4.00022-5",

language = "English",

isbn = "9780323904292",

pages = "561--591",

editor = "Elke Gasthuys and Karel Allegaert and Lien Dossche and Mark Turner",

booktitle = "Essentials of Translational Pediatric Drug Development",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Pediatric drug formulations

AU - Batchelor, Hannah

AU - Al-Obaidi, Issraa

AU - Harada, Tsutomu

AU - Saito, Jumpei

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Age-appropriate drug formulations are not always readily available, which historically has led to sub-optimal therapy for children. Legislation introduced in the past 20 years has required that pediatric drug formulations are required for any newly licensed drug (unless a waiver is agreed). This chapter will highlight the unique challenges associated with the design and development of pediatric formulations. It will also provide an overview of the progress and the innovations as well as the challenges and the opportunities related to pediatric-adapted drug formulation development.

AB - Age-appropriate drug formulations are not always readily available, which historically has led to sub-optimal therapy for children. Legislation introduced in the past 20 years has required that pediatric drug formulations are required for any newly licensed drug (unless a waiver is agreed). This chapter will highlight the unique challenges associated with the design and development of pediatric formulations. It will also provide an overview of the progress and the innovations as well as the challenges and the opportunities related to pediatric-adapted drug formulation development.

KW - Acceptable

KW - Age-appropriate

KW - Design

KW - Development

KW - Excipient

KW - Formulation

KW - Oral medications

KW - Palatable

KW - Pediatric

KW - Taste-masking

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85202876840&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-88459-4.00022-5

DO - 10.1016/B978-0-323-88459-4.00022-5

M3 - Chapter

AN - SCOPUS:85202876840

SN - 9780323904292

SP - 561

EP - 591

BT - Essentials of Translational Pediatric Drug Development

A2 - Gasthuys, Elke

A2 - Allegaert, Karel

A2 - Dossche, Lien

A2 - Turner, Mark

PB - Elsevier

ER -

Pediatric drug formulations

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this